BioGenesis is a San Diego-based biotechnology company that has raised $42 million in Series A funding, positioning it as a well-capitalized player in the competitive biotech landscape. The company's name suggests involvement in biological genesis or creation processes, potentially focusing on areas such as synthetic biology, cell therapy, gene therapy, or regenerative medicine technologies.
San Diego's vibrant biotechnology cluster provides BioGenesis with access to world-class research institutions, a skilled workforce, and proximity to other innovative biotech companies. The substantial Series A funding of $42 million indicates strong investor backing and confidence in the company's technology platform and commercial potential. This level of funding typically supports significant research and development activities, clinical development programs, or advanced technology platforms. As an active company in the rapidly evolving biotech sector, BioGenesis appears well-positioned to advance its biological technologies toward commercial applications.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Jan 2026 | Series A | $42M | Flagship Pioneering |
A San Diego biotech company focused on biological genesis and creation processes, backed by $42M in Series A funding.
BioGenesis has raised $42M in total funding, with their most recent round being a Series A. The company operates in the Biotech sector.
BioGenesis operates in the Biotech sector. A San Diego biotech company focused on biological genesis and creation processes, backed by $42M in Series A funding.
